| Literature DB >> 36009781 |
David Zweiker1,2, Edita Pogran1,3, Laura Gargiulo3, Ahmed Abd El-Razek3, Ivan Lechner4, Ivan Vosko2, Stefan Rechberger5, Heiko Bugger2, Günter Christ6, Diana Bonderman6, Evelyn Kunschitz7, Clara Czedik-Eysenberg8, Antonia Roithinger3, Valerie Weihs1,8, Christoph C Kaufmann1, Andreas Zirlik2, Axel Bauer4, Bernhard Metzler4, Thomas Lambert5, Clemens Steinwender5, Kurt Huber1,3.
Abstract
BACKGROUND: Takotsubo syndrome (TTS) is an important type of acute heart failure with significant risk of acute complications and death. In this analysis we sought to identify predictors for in-hospital clinical outcome in TTS patients and present long-term outcomes.Entities:
Keywords: LVEF; neutrophile-lymphocyte ratio; outcome; predictors; registry; takotsubo syndrome
Year: 2022 PMID: 36009781 PMCID: PMC9404721 DOI: 10.3390/biology11081154
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Baseline characteristics of the total study population and stratified by subgroups based on occurrence of severe in-hospital complications. Severe in-hospital complications were all complications requiring immediate invasive therapy or leading to irreversible disability.
| Parameter | Total | No Complications | Complications | |
|---|---|---|---|---|
|
| ||||
| female sex | 86.9% ( | 87.5% ( | 83.3% ( | 0.486 |
| age | 72 (62–79) | 72 (62–79) | 73 (65–81) | 0.437 |
|
| ||||
| arterial hypertension | 61.7% ( | 61.5% ( | 63.3% ( | 0.875 |
| hyperlipidemia | 34.1% ( | 34.7% ( | 30.6% ( | 0.628 |
| history of coronary artery disease | 11.0% ( | 10.8% ( | 12.2% ( | 0.805 |
| atrial fibrillation | 12.8% ( | 12.5% ( | 14.3% ( | 0.816 |
| other supraventricular arrhythmia | 1.2% ( | 1.4% ( | 0% ( | 1.000 |
| chronic kidney disease | 13.6% ( | 10.4% ( | 32.7% ( | <0.001 * |
| COPD | 22% ( | 21.9% ( | 22.4% ( | 1.000 |
| diabetes mellitus type 2 | 15.7% ( | 14.6% ( | 22.4% ( | 0.201 |
| psychiatric disease | 21.4% ( | 22.9% ( | 12.2% ( | 0.130 |
| history of previous TTS | 1.2% ( | 1.4% ( | 0% ( | 1.000 |
| current smoker | 23.5% ( | 22.2% ( | 30.6% ( | 0.204 |
| previous smoker | 14.3% ( | 16.5% ( | 2% ( | 0.006 * |
|
| ||||
| emotional trigger | 21.9% ( | 24.2% ( | 8.2% ( | 0.014 * |
| physical trigger | 25.4% ( | 24.2% ( | 32.7% ( | 0.217 |
| both emotional and physical trigger | 4.3% ( | 4.3% ( | 4.9% ( | 0.695 |
| unclear trigger | 49.1% ( | 48.1% ( | 55.1% ( | 0.440 |
|
| ||||
| hs-troponin T (ng/L, | 192 (69–416) | 194 (75–417.75) | 138 (53–328) | 0.361 |
| hs-troponin I (pg/mL, | 3165 ± 3726 | 3165 ± 3726 | N/A | N/A |
| troponin I (ng/mL, | 1.82 (0.448–4.105) | 1.59 (0.448–4.023) | 2.215 (0.458–4.803) | 0.603 |
| elevated troponin | 97.7% ( | 97.3% ( | 100% ( | 0.592 |
| leukocytes at admission (G/L) | 9.88 (7.82–13.17) | 9.90 (7.81–12.99) | 9.61 (7.85–15.51) | 0.622 |
| CRP at admission (mg/L) | 5.4 (2.8–14.3) | 4.8 (2.8–12.6) | 9.2 (4.1–60.4) | 0.002 * |
| neutrophile granulocytes (G/L) | 7.3 (5.0–10.9) | 6.9 (5.0–10.4) | 9.3 (6.3–15.1) | 0.005 * |
| lymphocytes (G/L) | 1.7 (1.11–2.32) | 1.8 (1.2–2.4) | 1.5 (0.9–2.1) | 0.019 * |
| NLR at admission | 4.33 (2.51–7.93) | 4.05 (2.49–7.00) | 6.12 (3.40–15.09) | 0.002 * |
| nt-proBNP (pg/mL, | 2352 (742–6030) | 2417 (738–5799) | 1930 (784–7739) | 0.828 |
|
| ||||
| left ventricular ejection fraction (%, | 46.0 ± 13.7 | 48.0 ± 12.3 | 35.4 ± 15.4 | <0.001 * |
| right ventricular involvement ( | 5.4% ( | 5.0% ( | 7.4% ( | 0.639 |
| apical ballooning | 48.5% ( | 51.7% ( | 30.4% ( | 0.010 * |
| midventricular ballooning | 48.5% ( | 45.2% ( | 67.4% ( | 0.006 * |
| basal ballooning | 2.3% ( | 2.3% ( | 2.2% ( | 1.000 |
|
| ||||
| GEIST score [ | −0.4 (−0.5–19.5) | −0.4 (−0.5–19.5) | −0.2 (−0.4–19.6) | 0.034 * |
|
| ||||
| hospital stay (days) | 5 (3–10) | 5 (3–8) | 11 (6–25) | <0.001 * |
CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GEIST score: chronic kidney disease: eGFR < 60 mL/min at ≥2 measurements before the TTS event; NLR: neutrophile/lymphocyte ratio; TTS: Takotsubo syndrome. * p < 0.05.
Total, severe and other in-hospital complications in the whole study population.
| Complication | Proportion (Absolute Count) |
|---|---|
|
| 33.1% ( |
|
| 14.5% ( |
| cardiogenic shock | 9.8% ( |
| in-hospital death | 3.3% ( |
| respiratory failure requiring intubation | 1.2% ( |
| stroke | 0.6% ( |
| persistent ventricular tachycardia | 0.6% ( |
| ventricular fibrillation | 0.6% ( |
| symptomatic AV block | 0.3% ( |
| hypoxic brain injury | 0.3% ( |
|
| |
| respiratory failure without intubation | 7.7% ( |
| new-onset atrial fibrillation | 3.6% ( |
| acute kidney failure | 5.3% ( |
| Bleeding | 5.0% ( |
| atrial fibrillation | 3.6% ( |
| urinary tract infection | 3.6% ( |
| pneumonia | 2.7% ( |
| sepsis (without shock) | 1.5% ( |
| left-ventricular thrombus | 0.9% ( |
| mitral regurgitation (conservative treatment) | 1.2% ( |
| infection of unknown origin | 0.9% ( |
| pericardial effusion | 0.3% ( |
| enteritis | 0.3% ( |
| lower limb ischemia | 0.3% ( |
| aneurysma spurium | 0.3% ( |
AV: atrioventricular.
Figure 1Total and severe in-hospital complications in the whole study population.
Figure 2Rate of selected in-hospital complications across different NLR terciles.
Univariable and multivariable predictors of in-hospital complications.
| Univariable Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
| Parameter | OR (95% CI) | OR (95% CI) | ||
| age (per year) | 1.01 (0.98–1.04) | 0.437 | 1.00 (0.97–1.04) | 0.822 |
| chronic kidney disease | 4.18 (2.03–8.41) | <0.001 | 1.84 (0.78–4.37) | 0.164 |
| previous smoker | 0.11 (0.01–0.50) | 0.006 | 0.13 (0.02–1.06) | 0.056 |
| emotional trigger | 0.28 (0.08–0.72) | 0.014 | 0.55 (0.17–1.76) | 0.312 |
| CRP at admission | 1.01 (1.00–1.02) | 0.002 | 1.01 (1.00–1.02) | 0.076 |
| NLR at admission | 1.04 (1.02–1.07) | 0.002 | 1.04 (1.01–1.08) | 0.009 * |
| LVEF (per %) | 0.92 (0.90–0.95) | <0.001 | 0.93 (0.90–0.96) | <0.001 * |
| apical ballooning | 0.41 (0.20–0.79) | 0.010 | 0.78 (0.08–7.50) | 0.826 |
| midventricular ballooning | 2.51 (1.31–4.99) | 0.006 | 0.98 (0.10–9.84) | 0.986 |
* p < 0.05 in multivariable analysis.
Sub-group analysis.
| Subgroup |
| OR (95% CI) |
| |
|---|---|---|---|---|
| Age ≥ 70 years | 194 | 1.05 (1.01–1.09) | 0.006 | 0.622 |
| Age < 70 years | 128 | 1.04 (1.00–1.08) | 0.030 | |
| Female gender | 286 | 1.04 (1.02–1.07) | 0.003 | 0.676 |
| Male gender | 37 | 1.06 (1.00–1.16) | 0.098 | |
| LVEF ≥ 45% | 155 | 1.04 (1.00–1.07) | 0.028 | <0.001 |
| LVEF < 45% | 117 | 1.06 (1.02–1.12) | 0.008 |
Figure 3Cumulative five-year mortality in NLR terciles.
Figure A1Long-term survival stratified by LVEF terciles.